
    
      A randomized placebo-controlled, double-blind, two-period crossover study with an explorative
      design. 40 healthy males aged 31-59 years will be included in the study. Participant
      allocation to either Neurexan® or Placebo at study start is randomized with a ratio of 1:1,
      i.e. 20 Neurexan® first to 20 Placebo first individuals. Participants receive totally three
      tablets of either Neurexan® or Placebo per treatment period orally.
    
  